1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ADO-MM-PAL8, NCT00226473
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-1697, SWOG-E1697, CALGB-500103, CAN-NCIC-ME10, COG-E1697, E1697, NCT00003641, ME10
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, NCT00111007
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MM-ADJ-5, NCT00226408
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 9267-01, 2001-034, NCT00221702
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 05 DIVE 03, NCT00224744
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Other
Protocol IDs: BRD/04/1-D, NCT00200577
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: JWCI-MORD-LM/SL-CLND-1102, NCT00389571
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LX01-315, NCT00395070
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: A/100/0402, NCT00477906
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-029, EORTC 18071, NCT00636168
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 005/05, NCT00769704
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 101.321-13/07, EudraCT Nr. 2008-001686-28, NCT00779714
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111482, NCT00796445
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA033, NCT00864253
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TROG 08.09, 2009/039, NCT00975520
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13101, H8K-MC-JZAO, NCT01006252
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO25026, 2009-012293-12, NCT01006980
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: over 18
Sponsor: Other
Protocol IDs: ERLANGEN-ONTAK, EU-20246, NCT00056134
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ERLANGEN-DERMA-ER-DC-06, EU-20317, NCT00074230
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: RNA-Mel-03, NCT00204516
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2333, PHI 0241, NCT00209248
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NU-05M1, NU-0310-093, SPRI-NU-05M1, NCT00301067
|
